FDA goes soft on Adderall labeling

In the months following an FDA advisory panel covering Adderall warnings, the FDA asked most the drug maker to add better warnings.

The FDA decision was barely made public. The FDA simply released a letter to GlaxoSmithKline, maker of Dexedrine, sent to doctors. Others include Adderall, Focalin, and Concerta. It is a meager effort on the part of the FDA not to warn the public of these dangers.

Some analysts and doctors say the warnings are unlikely to affect the millions of ADHD prescriptions written each month.

The FDA kept a lid on letting the public know of the dangers of Adderall. In near silence, FDA announced that it will require the makers of Adderall to add a label on Adderall announcing heart problems and psychiatric warnings. The poor effort of the FDA is now being questioned by politicians as to the FDA's loyalty toward pharmaceutical giants or the public safety. (Chron)